Last updated: October 01, 2026

Application No. 19/460,949

COMPOSITIONS AND METHODS FOR PROGRAMMED DEATH LIGAND RECEPTOR (PD-L1) EXPRESSION

Non-Final OA

Filed

Jan 27, 2026

Priority

Jul 28, 2023 — provisional 63/516,270 +1 more

Examiner

CHONG, KIMBERLY

Art Unit

1636

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Novo Nordisk Inc.

OA Round

2 (Non-Final)

Interview Optional

— +13.0% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 72% grant rate with +13.0% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 1501 resolved cases, 2023–2026

Examiner Intelligence

CHONG, KIMBERLY View full profile →

Grants 72% — above average

Career Allowance Rate

1087 granted / 1501 resolved

+12.4% vs TC avg

Moderate +13% lift

Without

With

+13.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 6m

Avg Prosecution

56 currently pending

Career history

1559

Total Applications

across all art units

Statute-Specific Performance

§101

3.9%

-36.1% vs TC avg

§103

31.1%

-8.9% vs TC avg

§102

17.1%

-22.9% vs TC avg

§112

33.3%

-6.7% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1501 resolved cases

Prosecution Timeline

Jan 27, 2026

Application Filed

Jun 17, 2026

Non-Final Rejection mailed

Aug 18, 2026

Applicant Interview (Telephonic)

Aug 27, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/185,743

Patent 12729378

MODULATING SYNGAP

3y 5m to grant Granted Sep 08, 2026

16/966,422

Patent 12708643

TREATMENT USING CYTOKINE ENCODING RNA

6y 0m to grant Granted Aug 18, 2026

17/817,588

Patent 12709749

ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES

4y 0m to grant Granted Aug 18, 2026

16/966,503

Patent 12697386

NUCLEIC ACID ANTIBODY CONSTRUCTS FOR USE AGAINST EBOLA VIRUS

6y 0m to grant Granted Aug 04, 2026

19/054,315

Patent 12673108

CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USE

1y 4m to grant Granted Jul 07, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3

Expected OA Rounds

72%

Grant Probability

85%

With Interview (+13.0%)

2y 6m (~1y 10m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 1501 resolved cases by this examiner. Grant probability derived from career allowance rate.